BPTF-silencing impairs cell proliferation and migration in PDA tumours, and strongly enhances the sensitivity to gemcitabine through the downregulation of ABC-transporters in a c-MYC-dependent manner. The gene discussed is MYC; the disease is Patent ductus arteriosus.